Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 869-875

  Taylor, Rebecca C ^a   Patel, Ami ^a   Panageas, Katherine S ^a   Busam, Klaus J ^a   Brady, Mary S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SEX RATIO; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; ADOLESCENT; AGED; CHILD; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 33947540564     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.9755     Document Type: Article

References (29)

1. Clark WH Jr, Elder DE, Guerry DT, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
2. Clemente CG, Mihm MC Jr, Bufalino R, et al: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310, 1996
3. Sondergaard K, Schou G: Survival with primary cutaneous malignant melanoma, evaluated from 2012 cases: A multivariate regression analysis. Virchows Arch A Pathol Anat Histopathol 406:179-195, 1985
4. Elder DE, Guerry DT, VanHorn M, et al: The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 56:413-418, 1985
5. Tuthill RJ, Unger JM, Liu PY, et al: Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118:504-511, 2002
6. Johnson OK Jr, Emrich LJ, Karakousis CP, et al: Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical stage I. Cancer 55:1107-1117, 1985
7. Larsen TE, Grude TH: A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I: 3, The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol Microbiol Scand 86A:523-530, 1978
8. Barnhill RL, Fine JA, Roush GC, et al: Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78:427-432, 1996
9. Thorn M, Ponten F, Bergstrom R, et al: Clinical and histopathologic predictors of survival in patients with malignant melanoma: A population-based study in Sweden. J Natl Cancer Inst 86:761-769, 1994
10. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
11. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al: Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol 134:983-987, 1998
12. Berk DR, Johnson DL, Uzieblo A, et al: Sentinel lymph node biopsy for cutaneous melanoma: The Stanford experience, 1997-2004. Arch Dermatol 141:1016-1022, 2005
13. Sondak VK, Taylor JM, Sabel MS, et al: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11:247-258, 2004
14. Lowe JB, Hurst E, Moley JF, et al: Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 139:617-621, 2003
15. Kruper L, Botbyl B, Czerniecki B, et al: Sentinel lymph node status in stage II/III melanoma. J Clin Oncol 23:710S, 2005 (suppl; abstr 7501)
16. Clary BM, Brady MS, Lewis JJ, et al: Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 233:250-258, 2001
17. Busam KJ, Antonescu CR, Marghoob AA, et al: Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: A study of interobserver agreement. Am J Clin Pathol 115:856-860, 2001
18. Gershenwald JE, Thompson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983, 1999
19. Kopf AW, Welkovich B, Frankel RE, et al: Thickness of malignant melanoma: Global analysis of related factors. J Dermatol Surg Oncol 13:345-390, 401-420, 1987
20. Elder DE, Gimotty PA, Guerry D: Cutaneous melanoma: Estimating survival and recurrence risk based on histopathologic features. Dermatol Ther 18:369-385, 2005
21. Lowes MA, Bishop GA, Crotty K, et al: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 108:914-919, 1997
22. Wagner SN, Schultewolter T, Wagner C, et al: Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 78:541-550, 1998
23. Conrad CT, Ernst NR, Dummer W, et al: Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res 18:225-232, 1999
24. Reed JA, McNutt NS, Prieto VG, et al: Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion: Implications for tumor progression. Am J Pathol 145:97-104, 1994
25. Halliday GM, Patel A, Hunt MJ, et al: Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells. World J Surg 19:352-358, 1995
26. Pages F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666, 2005
27. Viguier M, Lemaitre F, Verola O, et al: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444-1453, 2004
28. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004
29. Sasada T, Kimura M, Yoshida Y, et al: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 98:1089-1099, 2003